Adoptive Cell Therapy is a method treating certain blood cells – the lymphocytes – which are isolated from the patient. The blood cells are then modified, cultivated and expanded outside the body to recognize and kill cancer cells. After the ex-vivo process cells are subsequently returned to the patient in very large numbers.
Several studies performed in the US and Europe on e.g., skin cancer (malignant melanoma) have shown adoptive cell therapy methods to be an effective and gentle therapy. However, previously existing methods were technically complicated and time-consuming, and hence were not implemented as a “standard of care” method for cancer therapy.
Cytovac’s ALECSAT therapy represents an adoptive cell therapy method, which is simple to perform. The finished product can be manufactured in only 20 days after initial blood sample is collected from the patient. Only small blood volumes from the patient are required – no tumor material, no foreign peptides, proteins or genetically manipulated cells.
Today, Cytovac is manufacturing ALECSAT on a routine basis for the treatment of patients participating in different clinical trials.
More than 100 patients have received treatments, many of them on multiple occasions.